At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 145 enrolled
Drug / intervention
AVP-786 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Sequential Parallel Comparison Design (SPCD) Study to Assess the Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) as an Adjunctive Treatment for Patients With Residual Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Jun 23, 2015·Updated May 13, 2026
In Brief
A Phase 2 clinical trial evaluating AVP-786 and Placebo for Schizophrenia. Completed, enrolled 145 participants across 17 sites.
Detailed Summary
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartSep 2015
Primary CompletionJul 2017
TodayJul 2026
First PostedJun 23, 2015
Enrollment StartSep 1, 2015
Primary CompletionJul 21, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.0 years ago
Interventions
AVP-786drug
Placebodrug